Eyenovia Inc. Report issue

For profit Phase 3 Phase 4
Founded: New York NY United States (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2016
NCT02946125
First Marketed Drug
2023
tropicamide (mydriacyl)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

EYENOVIA | Eyenovia Inc.

Active Ingredients

Marketed Drugs (2)

phenylephrine (Prefrin) (2023)

tropicamide (mydriacyl) (2023)

Drugs in Phase 4 Trials (2)

phenylephrine (Prefrin) (4 trials)

tropicamide (mydriacyl) (3 trials)

Drugs in Phase 3 Trials (2)

atropine (1 trial)

pilocarpine (ocusert) (2 trials)

Drugs in Other Trials (1)

latanoprost (xalatan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Mydriasis (Phase 3)

Myopia (Phase 3)

Presbyopia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 5